Search Bar & Filters
Found 3 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the real-world effectiveness, safety, and patient compliance of ribociclib combined with an aromatase inhibitor for adjuvant treatment in patients with hormone receptor-positive, HER2-negative early breast cancer at high risk of recurrence. This observational study also compares ribociclib treatment with abemaciclib plus endocrine therapy and endocrine therapy alone, aiming to better understand treatment decisions and clinical adoption in routine practice. The study is conducted across breast centers and gynecological practices to represent typical healthcare settings. Participants receive treatment based on their physicians clinical judgment without randomization or intervention assignment. The study collects data from patients treated with ribociclib plus aromatase inhibitor with or without luteinizing hormone-releasing hormone LHRH, abemaciclib plus endocrine therapy with or without LHRH, or endocrine therapy alone with or without LHRH. Baseline data and follow-up information on adverse events, quality of life, treatment adherence, and socio-economic factors are gathered over time. During the study, participants undergo assessments including evaluation of invasive disease-free survival up to 36 months, quality of life questionnaires, medication adherence reports, and monitoring of adverse events and treatment changes. Data on reasons for treatment decisions, patient perceptions, and healthcare provider involvement are also collected. The study duration extends up to 39 months to provide a comprehensive overview of treatment impact and patient experience in real-world clinical settings.
Actively Recruiting
Researchers are investigating the real-world use and effects of ovarian function suppression OFS combined with endocrine therapy in pre- and perimenopausal women with breast cancer who have low genomic risk according to MammaPrint testing. The study aims to understand differences in treatment outcomes based on menopausal status, chemotherapy use, and endocrine therapies, with a focus on adherence and quality of life over time. This observational registry will collect data to provide insights into treatment paths, outcomes, and factors influencing prognosis in these patients. Participants receive standard-of-care endocrine therapy with or without ovarian suppression and may have received chemotherapy based on clinical decisions and genomic risk assessments. The registry observes various treatment approaches in a real-world setting, including management of ovarian function, and follows patients for up to 10 years. Quality of life assessments occur regularly during the first five years, and treatment adherence is monitored throughout the study period. During the study, participants medical data including baseline characteristics, treatment details, relapse information, and quality of life questionnaires will be collected at multiple time points. Researchers will evaluate outcomes such as distant recurrence-free interval, disease-free survival, overall survival, and endocrine response over 5 to 10 years. The long-term follow-up allows for detailed monitoring of treatment adherence and correlation of genomic and clinicopathological markers with patient outcomes.
Actively Recruiting
Researchers are observing patients with documented HER2-positive, HER2-low, or HER2-ultralow unresectable or metastatic breast cancer who are receiving trastuzumab deruxtecan T-DXd treatment. The study evaluates patient-reported outcomes as well as real-world effectiveness and safety of T-DXd when used according to the approved product guidelines within routine clinical practice in Germany. Additionally, patients will be informed about using a digital healthcare application DiGA. Participants receive T-DXd treatment as part of their routine care, with no specific treatment schedule dictated by the study protocol. The study includes two groups one with HER2-positive breast cancer patients and another with HER2-low or HER2-ultralow patients, each group expected to enroll approximately 400 participants. All diagnostic and treatment decisions, including visit frequency, are managed by the treating physician. During the study, participants health and treatment progress will be tracked, including patient-reported quality of life assessments using FACT-B and FACT-G questionnaires at six months. Researchers will monitor the time from first T-DXd dose to the next treatment or death, assessed for up to 60 months. The study lasts until December 2031, with ongoing observation of real-world treatment outcomes and safety.